Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 10Neoplasms 6Lymphoma, Non-Hodgkin 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm Metastasis 4Lymphoma 4Leukemia 4Hodgkin Disease 4Burkitt Lymphoma 4Breast Neoplasms 4Vomiting 3Prostatic Neoplasms 3Lymphoma, B-Cell 3Lung Neoplasms 3Leukemia, Hairy Cell 3Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Stomatitis 2Stomach Neoplasms 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Nausea 2Myelodysplastic Syndromes 2Mucositis 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2

Interventions

Dexamethasone 6Lenalidomide 4Bortezomib 4pomalidomide 3isatuximab 2daratumumab 2ricolinostat 1nirogacestat 1ficlatuzumab 1Zoledronic Acid 1Vorinostat 1Ranitidine 1KW-2478 1Hsp90 inhibitor KU757 1Erlotinib Hydrochloride 1Diphenhydramine 1Denosumab 1Cyclophosphamide 1CLR1404 1Acetaminophen 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blood Protein Disorders × Diphenhydramine × Clear all
NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡